Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) has received a consensus rating of "Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $24.20.

Several brokerages have recently issued reports on TSHA. Chardan Capital reduced their price target on shares of Taysha Gene Therapies from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Friday, August 12th. Guggenheim reduced their target price on shares of Taysha Gene Therapies to $22.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Needham & Company LLC reduced their target price on shares of Taysha Gene Therapies to $20.00 and set a "buy" rating on the stock in a report on Tuesday, May 17th. Wedbush reduced their target price on shares of Taysha Gene Therapies from $9.00 to $5.00 and set an "outperform" rating on the stock in a report on Friday, August 12th. Finally, The Goldman Sachs Group reduced their target price on shares of Taysha Gene Therapies from $27.00 to $16.00 and set a "buy" rating on the stock in a report on Tuesday, May 24th.

Insider Activity at Taysha Gene Therapies

In related news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction on Friday, July 1st. The shares were sold at an average price of $3.53, for a total value of $84,448.19. Following the transaction, the chief marketing officer now directly owns 543,450 shares in the company, valued at approximately $1,918,378.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CMO Suyash Prasad sold 23,923 shares of Taysha Gene Therapies stock in a transaction on Friday, July 1st. The shares were sold at an average price of $3.53, for a total value of $84,448.19. Following the transaction, the chief marketing officer now directly owns 543,450 shares in the company, valued at approximately $1,918,378.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Kamran Alam sold 9,717 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $3.50, for a total transaction of $34,009.50. Following the sale, the chief financial officer now owns 269,446 shares in the company, valued at $943,061. The disclosure for this sale can be found here. Insiders have sold a total of 57,345 shares of company stock worth $208,051 in the last three months. Insiders own 42.40% of the company's stock.

Institutional Inflows and Outflows

Taysha Gene Therapies Stock Up 11.4 %

Shares of TSHA opened at $3.42 on Monday. The stock has a market capitalization of $140.54 million, a PE ratio of -0.71 and a beta of 1.09. Taysha Gene Therapies has a 1 year low of $2.33 and a 1 year high of $21.29. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.79 and a current ratio of 1.79. The company's 50-day simple moving average is $3.96 and its 200-day simple moving average is $4.37.

About Taysha Gene Therapies

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Read More

• Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
• Can Electronic Arts Buck the Downturn in Videogaming?
• Dollar General is the Big Fish in Little Ponds Across the U.S.
• Here's Why the CPI Report will Dictate the Market Bottom
• MarketBeat: Week in Review 9/5 – 9/9
• Prepare For A Record-Setting Quarter For Cyber Security Stocks

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.